v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Activities:    
Net loss $ (4,541) $ (3,014)
Adjustments to reconcile net loss to cash flows used in operating activities:    
Depreciation and amortization 38 73
Stock-based compensation expense 25 67
Change in fair value of warrant liabilities (26) (40)
Non-cash IP R&D from Rendiatech acquisition 757 0
Changes in operating assets and liabilities:    
Accounts receivable (66) 187
Inventory, net 181 (34)
Other current assets 293 41
Other assets Other liabilities (171) 45
Accounts payable and accrued expenses 398 139
Net cash used in operating activities (3,112) (2,536)
Investing Activities:    
Purchases of property and equipment (30) 0
Purchase of intangible assets (90) 0
Cash paid for acquisition of Rendiatech, net of cash acquired (164) 0
Net cash used in investing activities (284) 0
Financing Activities:    
Issuance of common stock and warrants from offering, net 4,393 0
Non-cash Series J deemed dividend 2 0
Net cash provided by financing activities 4,395 0
Effect of exchange rate changes on cash 0 (2)
Net increase (decrease) in cash and cash equivalents 999 (2,538)
Cash and cash equivalents, and restricted cash - beginning of period 1,190 5,095
Cash and cash equivalents, and restricted cash - end of period 2,189 2,557
Supplemental cash flow information    
Common stock issued as consideration in asset acquisition 162 0
Transaction costs in accounts payable 164 0
Deferred costs issued as consideration in asset acquisition 313  
Deemed dividend on Series J Preferred Stock $ 2 $ 1